Bevacizumab, a humanized monoclonal antibody that binds all forms of VEGF-A, was FDA-approved for the treatment of NSCLC in 2006 [27] but has limited efficacy against SCLC when combined with chemotherapy [28–35]. This evidence concerns the gene VEGFA and small cell lung carcinoma.